Quick Answer
VYNE Therapeutics Inc. reported Cash And Cash Equivalents At Carrying Value of $24.03 million for the year ending 2025.
- VYNE Therapeutics Inc. showed an increase of +20.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from VYNE Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), VYNE Therapeutics Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 8,701.1%.
- Historical annual values: Fiscal year 2025: $24.03 million | Fiscal year 2024: $19.93 million | Fiscal year 2023: $30.62 million | Fiscal year 2022: $30.91 million | Fiscal year 2021: $42.25 million | Fiscal year 2020: $57.56 million | Fiscal year 2019: $43.76 million | Fiscal year 2018: $27.87 million | Fiscal year 2017: $10.21 million | Fiscal year 2016: $4.03 million | Fiscal year 2015: $43.81 million | Fiscal year 2014: $273.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: